This case highlights the diagnostic and management challenges of refractory multisystem sarcoidosis progressing over a two-year period despite advanced biologic therapy.
🎯 Background & Rationale
While robotic-assisted bronchoscopy (RAB) has revolutionized the sampling of peripheral pulmonary lesions, previous literature has been limited to single-arm studies evaluating platforms (primarily the Monarch and Ion systems) in isolation. Due to varying diagnostic yield definitions and disparate patient cohorts, direct comparisons between platforms have been lacking. This study addresses the clinical gap by providing the first direct comparative analysis between the Monarch and Ion robotic bronchoscopy platforms.
👥 Study Design & Population
- Study Type: Single-center retrospective observational cohort study with propensity score-matched analysis.
- Population: 365 adult patients who underwent RAB biopsy of a single target pulmonary lesion (Monarch N = 162, Ion N = 203) between November 2021 and December 2023 in a sequential, non-overlapping timeframe.
📈 Methodology & Rigor
To minimize selection bias between the nonrandomized, sequentially introduced groups, the authors performed 1:1 propensity score matching utilizing a genetic search algorithm (GenMatch in R) matching for age, sex, nodule size, location, and presence of a bronchus sign. Diagnostic yield (DY) was defined strictly using criteria endorsed by the American Thoracic Society and ACCP. Primary outcomes (DY and pneumothorax) were evaluated using conditional logistic regression, while quantitative outcomes (procedure and radiation metrics) utilized mixed models treating matches as random factors.
🔬 Key Findings [or Planned Endpoints]
- Diagnostic Yield: The Ion platform demonstrated a significantly higher unadjusted diagnostic yield compared to Monarch (84.2% [171/203] vs. 71.0% [115/162], P = 0.003), supported by propensity score matching (adjusted OR: 2.29, 95% CI: 1.42–3.70).
- Procedural Efficiency: Ion cases had significantly shorter robot procedure times (median 37.0 vs. 70.0 min, P < 0.001), radiation duration (4.6 vs. 8.0 min, P < 0.001), and lower radiation dose area product (DAP: 22.7 vs. 40.0 Gy·cm², P < 0.001).
- Complications: Pneumothorax rates were 1.0% (Ion) versus 4.3% (Monarch), showing a lower adjusted risk for pneumothorax with Ion (adjusted OR: 0.13, 95% CI: 0.03–0.62).
- Confounders: A 1.1 mm cryoprobe was utilized in 193/203 Ion cases versus only 10/162 Monarch cases. Cone-beam CT (CBCT) integration with the Cios system was utilized more frequently with Monarch (95.1%) than Ion (80.3%).
⚖️ Critical Appraisal
Internal validity is strengthened by the rigorous propensity score matching and the application of a strict, standardized diagnostic yield definition. However, significant methodological limitations temper the conclusions:
- Confounding Variables: The study is heavily confounded by the near-exclusive use of the 1.1 mm cryoprobe in the Ion cohort versus the Monarch cohort, which may independently drive differences in diagnostic yield.
- Sequential Bias: Platforms were evaluated in non-overlapping historical time blocks (Monarch first, Ion second), raising the possibility of proceduralist learning curve bias.
- CBCT Integration: Differences in CBCT utilization and system integration features (such as Cios integration with Ion) introduce unmeasured technical variance.
💡 The Clinical Bottom Line
While this retrospective comparison suggests that the Ion platform yields higher diagnostic accuracy with shorter procedure times and lower radiation exposure compared to Monarch, definitive superiority cannot be claimed due to substantial confounding variables—specifically the asymmetric adoption of the 1.1 mm cryoprobe and procedural learning curves. Clinicians must await data from properly randomized controlled trials (such as FROSTBITE-II) before altering platform preference based on retrospective data alone.
Abstract
Keep reading
N opens the next oneClinicians should note that the presence of targetable mutations in non-small cell lung cancer with malignant pleural disease is not associated with improved survival, based on the findings from this study.
Shape-sensing robotic-assisted bronchoscopy achieved a strict diagnostic yield of 70.2% with a low pneumothorax rate of 3.3%, demonstrating that earlier tissue diagnosis of very small pulmonary nodules is feasible and safe for clinical practice.
CT-guided fiducial placement remains a relevant technique for pre-procedural localization of peripheral lung lesions.
This study introduces ultrasound-guided trans-cannula cryobiopsy of supraclavicular lymph nodes as a novel superficial lymph node approach for tissue acquisition in 10 consecutive patients, though specific numeric success or safety results were not provided in the abstract.
Active infection is not an absolute contraindication to endobronchial valve placement, but positive pressure ventilation significantly increases clinical failure odds with an aOR of 3.00 at P < 0.001.